查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1857733

人源化小鼠和大鼠模型市场（按模型类型、应用、最终用户和产品类型划分）—2025-2032年全球预测

Humanized Mouse & Rat Model Market by Model Type, Application, End User, Product Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，人源化小鼠和大鼠模型市场将成长至 4.9448 亿美元，复合年增长率为 7.56%。

关键市场统计数据
基准年 2024 2.7591亿美元
预计年份：2025年 2.9724亿美元
预测年份 2032 4.9448亿美元
复合年增长率 (%) 7.56%

专家概述了人源化小鼠和大鼠模型的创新如何重塑前临床开发平臺和转化研究重点。

人源化小鼠和大鼠模型已成为现代临床前研究的重要工具，为免疫学、感染疾病、肿瘤学、神经病学和心血管科学等领域的转化研究提供了重要依据。这些人工建构的、源自患者的模型系统，透过提供生理相关的环境，日益弥合了体外研究结果与临床现实之间的差距，使研究人员能够深入探讨人类特异性的免疫相互作用、病原体趋向性和肿瘤生物学特性。随着实验目标的日益复杂，研究人员和产品开发人员正在寻求更逼真的模型、更可靠的表征方法以及能够加快获得可操作资料速度并提高实验可重复性的综合服务。

因此，供应商、合约研究机构和学术联盟已扩展其产品组合，纳入高度人源化的大鼠变体、更广泛的免疫力缺乏品系、患者来源的异质骨移植模型库以及精准的转基因构建体。同时，基因组编辑、育种和饲养技术的进步，以及表型分析和生物检测能力的增强，重塑了申办者设计临床前计画的方式。本导言重点阐述了当前情势下营运的复杂性和科学机会，并为深入分析影响模型选择、筹资策略、监管环境和最终用户偏好的结构性变化奠定了基础。

基因组工程、PDX技术以及整合服务交付的进步如何重新定义转化价值和实验可重复性

由于技术、操作和科学力量的融合，人源化囓齿动物模型领域正在经历显着的变化。首先，精准的基因组工程和先进的免疫移植方法提高了人源化免疫系统和器官特异性表型的保真度，从而能够更有效地评估免疫疗法和生技药品的疗效。同时，患者来源的异质骨移植模型库的广泛应用以及冷冻保存技术的改进，有助于保持肿瘤的异质性和临床相关性，从而加速转化肿瘤学计画的进展。

同时，业界正朝着模组化服务模式发展，将模型交付、效能测试和筛检服务整合在一起，以简化申办方的工作流程并减少行政障碍。监管的加强和对可重复性的日益增长的期望，促使企业采用更严格的文件记录、标准化的终点指标和第三方品质审核。此外，将体内数据与多组体学读数和高级分析进行计算整合，正逐渐成为机制阐明和研究设计优化的核心竞争力。总而言之，这些转变正在促进一个更协作的生态系统的发展，在这个生态系统中，多学科伙伴关係、垂直整合和基于平台的方法定义了竞争优势和科学价值。

评估2025年关税调整如何影响临床前研究生态系统的供应韧性、筹资策略和供应商多元化。

2025年前后实施的累积政策调整和关税措施对依赖专业动物模型和持续实验室投入的机构的供应链和营运规划产生了多方面的影响。对许多终端使用者而言，最直接的影响是进口种畜、专用耗材和某些试剂的到岸成本增加，促使采购团队重新谈判供应商合约、合併订单，并优先选择製造地分布在各地的供应商。作为应对措施，一些供应商采取了相应措施，包括转移关键生产过程、尽可能提高国内产能以及扩大本地库存以适应更长的前置作业时间。

除了直接的成本影响外，关税也在影响筹资策略和供应商选择决策，凸显了合约弹性和透明的前置作业时间承诺的重要性。在某些情况下，跨境物流变得更加难以预测，促使申办方加快采用替代模式和供应商检验计划，以确保实验按时完成。此外，贸易政策的调整增加了合规要求和文件负担，迫使实验室和采购团队加强海关专业知识和风险管理实践。总而言之，这些动态正在推动供应链网路朝向更具韧性的方向发展，更加重视供应商资格确认，并增加对冗余系统的策略性投资，以保障关键的临床前工作流程。

深度细分智能揭示了模型类型、应用重点、最终用户优先级以及产品服务组合如何驱动采购和研发选择。

按模型类型、应用、最终用户和产品类型分析人源化囓齿动物模型市场，揭示了其对研发规划者和采购负责人的策略意义。按模型类型划分，该市场包括人源化大鼠模型、免疫力缺乏模型、PDX模型和基因转殖模型。人源化大鼠模型包括hACE2大鼠模型和hCD4大鼠模型，它们分别与病毒嗜性和免疫肿瘤学研究密切相关。其他免疫力缺乏模型包括NOG、NSG和SCID模型，这些模型在移植效率、免疫表型以及与各种异种移植和人体免疫系统重建流程的兼容性方面各不相同。患者来源的异种移植模型涵盖乳癌、结肠癌和肺癌PDX模型，提供疾病特异性的保真度，以支持治疗假设检验和生物标记发现。用于机制阐明和标靶检验的转基因模型包括基因敲入模型和基因敲除模型，每种模型在研究基因功能和路径调控方面都具有独特的优势。

根据应用领域，我们的产品组合满足心血管、免疫学、感染疾病、神经病学和肿瘤学的研究需求。循环系统应用包括支持药物安全性和机制研究的动脉粥状硬化和高血压模型；免疫系统应用包括对生技药品开发至关重要的自体免疫和发炎性疾病模型。感染疾病应用分为细菌感染模型和病毒感染模型，此区分指南根据宿主易感性和生物安全性进行选择。神经病学应用包括有助于开发中枢神经系统标靶治疗方法的神经退化性疾病和疼痛模型。肿瘤学应用根据肿瘤微环境的考量分为血液肿瘤模型和固态肿瘤模型。最终用户分为学术研究机构、受託研究机构、製药公司和生技公司，每家机构的采购时间、检验阈值和服务偏好各不相同。最后，产品类型包括模型产品和服务。模型产品细分为市售模型和客製化模型，以满足现成产品和客製化开发的需求。另一方面，服务包括疗效测试服务、模型开发服务以及支援研究实施和转化验证的筛检服务。

综合以上几个方面，我们发现模型选择决策越来越受到生物学保真度、服务整合和操作确定性等因素的共同驱动。专注于免疫疗法的申办者通常倾向于选择特征明确的免疫力缺乏细胞系和定制的人源化构建体，而肿瘤团队则往往优先考虑能够保留肿瘤异质性的PDX模型。同时，製药和生技公司重视符合GLP规范的供应商、可重复的供应链以及承包服务包。服务差异化，尤其是在模型开发和疗效测试方面，是关键的竞争优势，能够帮助供应商建立长期伙伴关係，并减少复杂专案中的交易摩擦。

区域对比分析详细阐述了美洲、欧洲、中东和非洲以及亚太地区各自的优势如何影响模式采购、合规和服务采用。

区域动态对供给侧能力、调节互动以及人源化囓齿动物模型的应用轨迹产生不同的影响。在美洲，生物中心的集中、强大的转化研发管线以及成熟的合约研究产业，为先进人源化构建体和PDX平台的广泛应用提供了有力支撑。该地区拥有完善的研究设施基础设施和强大的服务供应商网络，降低了复杂体内实验项目的进入门槛。相较之下，欧洲、中东和非洲地区（EMEA）的情况则较为复杂，学术中心和专业服务提供者的优势领域与不同的法规结构和报销环境并存。这种多样性为跨境合作和专业化细分服务创造了机会，但也要求各方谨慎应对动物福利标准和进出口法规的差异。

亚太地区在育种设施、合约研究组织（CRO）服务和转化研究中心方面正经历着快速的产能扩张，同时，本土开发的模式生物品系数量不断增加，并日益重视本地试剂生产。因此，该地区为开展大规模临床前计画的相关人员提供了具有竞争力的价格和规模优势。在所有地区，物流因素、海关流程和区域政策变更都会影响前置作业时间和供应商选择。因此，跨国计画通常采用混合筹资策略，将本地能力用于常规测试，并与国际合作伙伴合作开发高度专业或检验的模式生物系统。

供应商策略、服务整合、专有模型开发和伙伴关係等方面的竞争考察，这些因素共同决定了临床前测试服务的竞争优势。

供应商和服务供应商之间的竞争动态呈现出专业化和整合并存的特点，各公司都在追求垂直整合、专有模型库和增值服务组合。领先的服务供应商正在增加对冷冻保存的PDX库、先进的表型分析平台和专有的人源化方案的投资，以确保与客户建立长期的合作关係并实现技术差异化。同时，委外研发机构（ CRO）正透过策略联盟、产能投资以及增建符合GLP规范的设施来扩展其体内研究能力，以支持后期治疗计画。

技术创新主要集中在提高移植效率、降低异质骨移植变异性以及扩展基因转移构建体的种类，以应对特定的机制问题。在品质系统、可追溯性和监管文件方面表现卓越的供应商，在与大型製药公司合作时具有竞争优势，因为这些公司对供应商资格要求非常严格。此外，整合模型开发、疗效测试和生物标记检测的服务模式，能够帮助供应商提升价值链，并获得更高的赞助商支出份额。最后，与学术中心和医院网路的合作日益普遍，这有助于获取用于构建PDX模型的新鲜肿瘤检体，并促进转化医学合作，从而加速目标检验和临床转化。

领导者可以采取哪些切实可行的策略步骤来增强供应商的韧性、转化相关性、监管反应能力和服务整合能力？

产业领导者可以采取一系列切实可行的措施，增强其在不断发展的人源化囓齿动物生态系统中的营运韧性、科学严谨性和商业性地位。首先，应优先考虑供应商资质资格确认流程，包括记录繁殖记录、基因检验和移植性能，并将这些标准纳入长期采购合同，以减少差异。其次，应投资关键模型和试剂的双重筹资策略和区域冗余，以减轻政策变化和物流限制带来的干扰，并确保研究按时完成。

第三，我们将发展内部转化检测开发和数据整合能力，从而更便捷地将体内研究结果与多组体学和影像学读数整合，以提升临床前项目的预测价值。第四，我们将与CRO合作伙伴协商服务水准承诺，包括明确的时间表、紧急应变计画和双方共同的绩效指标，以协调奖励并减少后续延误。第五，我们将加快在各项研究中采用标准化报告格式和元资料框架，以提高研究结果的可重复性并促进与监管机构的沟通。第六，我们将寻求与临床中心和生物样本库的策略合作，以扩大PDX（患者来源异种移植模型）的获取途径，并提高转化相关性。第七，我们将投入资源，持续进行员工在动物福利、生物安全和法规遵从方面的培训，以确保研究的伦理性和高品质。最后，我们将评估我们专有模型和平台服务的商业化机会，在许可潜力与规模化和品质保证的营运需求之间取得平衡。

我们采用透明、三角验证的研究途径，结合专家访谈、文件分析和检验检查，为相关人员提供可靠的策略见解。

本分析的调查方法结合了结构化的初步研究、严谨的二手资料审查和迭代检验，以确保研究结果的可靠性和可操作性。初步研究包括对科学研究负责人、采购经理和合约研究组织（CRO）高阶主管的访谈，以了解实际决策标准、前置作业时间敏感性以及不断变化的服务期望。二手资料审查涵盖了同行评审文献、监管指导文件、产品技术文献和营运报告，以梳理技术发展轨迹和品质标准。这些定性资讯和文献资料被整合起来，用于建构市场细分框架、供应链影响情境分析和区域比较评估。

为确保结论的有效性，我们采用了三角验证法，将访谈内容与供应商文献和营运绩效指标进行交叉比对，并进行了后续咨询以解决任何差异。品管程序包括标准化的访谈指南、资讯来源归属记录以及记录关键假设的可重复性检查清单。我们认识到，我们的方法受限于供应商特定数据和快速变化的政策环境。因此，我们建议读者将我们的研究结果视为策略指导，在製定采购和研发决策时，应结合公司本身的实质审查。

最后总结指出，整合科学严谨性、供应商合格和营运弹性对于转换成功至关重要。

总之，人源化小鼠和大鼠模型是实验生物学与临床应用之间的关键纽带，在基因工程、PDX保存和整合服务交付等领域的持续创新推动下，它们正在重新定义临床前策略。技术进步、监管预期和供应链动态之间的相互作用，迫使申办方采用更精细的采购、资格确认和合作方式。随着关税和政策环境的演变，那些投资于供应商多元化、严谨的文件记录和转化检测整合的机构，将更有利于保持专案进展势头，并从体内试验中获得更高的预测价值。

最终，竞争格局将青睐那些兼具卓越科学水准和严谨营运能力的公司。那些能够提供高度可重复、特征明确的模型以及承包服务的公司，将能够加深与申办者的合作，并支持其快速决策。透过应用本文提出的细分洞察、区域考量和可操作建议，相关人员可以将他们的临床前策略与科学重点和营运实际情况相结合，从而加速治疗药物的研发并降低风险。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • CRISPR/Cas9修饰的人源化小鼠模型的广泛应用提高了免疫肿瘤学研究的可重复性。
  • 在临床前研究中，对人源化大鼠模型的需求不断增长，以改善药物动力学和毒性分析。
  • 整合多组体学和人源化囓齿动物模型，加速个人化医疗和生物标记发现
  • 生技公司与学术机构合作开发下一代人源化囓齿动物平台
  • 新兴市场对人源化动物模型服务的需求成长，主要受生技药品研发管线投资增加的推动。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依模型类型分類的人源化小鼠和大鼠模型市场

  • 人源化大鼠模型
    • hACE2 大鼠模型
    • hCD4 大鼠模型
  • 免疫力缺乏模型
    • NOG模型
    • NSG模型
    • SCID模型
  • PDX 型号
    • 乳癌PDX
    • 大肠直肠癌PDX
    • 肺癌PDX
  • 基因改造模型
    • 敲入式模型
    • 淘汰赛模特儿

9. 按应用分類的人源化小鼠和大鼠模型市场

  • 心血管系统
    • 动脉硬化模型
    • 高血压模型
  • 免疫学
    • 自体免疫疾病模型
    • 发炎性疾病模型
  • 感染疾病
    • 细菌感染模型
    • 病毒感染模型
  • 神经病学
    • 神经退化性疾病模型
    • 疼痛模型
  • 肿瘤学
    • 血液学模型
    • 固态肿瘤模型

第十章 人源化小鼠和大鼠模型市场（依最终用户划分）

  • 学术研究机构
  • 受託研究机构
  • 製药和生物技术公司

第十一章 人源化小鼠和大鼠模型市场（依产品类型划分）

  • 模型产品
    • 商业模式
    • 客製化模型
  • 服务
    • 功效测试服务
    • 模型开发服务
    • 筛检服务

12. 各地区人源化小鼠与大鼠模型市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 人源化小鼠和大鼠模型市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国人源化小鼠与大鼠模型市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Charles River Laboratories International, Inc.
    • The Jackson Laboratory, Inc.
    • Taconic Biosciences, Inc.
    • Inotiv, Inc.
    • PerkinElmer, Inc.
    • Crown Bioscience International, Inc.
    • Biocytogen Pharmaceuticals Ltd.
    • BioIVT, Inc.
    • Cyagen Biosciences Inc.
    • GemPharmatech Co., Ltd.
Product Code: MRR-961BA04A2E3A

The Humanized Mouse & Rat Model Market is projected to grow by USD 494.48 million at a CAGR of 7.56% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 275.91 million
Estimated Year [2025] USD 297.24 million
Forecast Year [2032] USD 494.48 million
CAGR (%) 7.56%

An expert overview of how humanized mouse and rat model innovations are reshaping preclinical pipelines and translational research priorities

Humanized mouse and rat models have emerged as indispensable tools in contemporary preclinical research, enabling translational insights across immunology, infectious disease, oncology, neurology, and cardiovascular science. These engineered and patient-derived systems increasingly bridge the chasm between in vitro findings and clinical reality by providing physiologically relevant contexts in which human-specific immune interactions, pathogen tropisms, and tumor biology can be interrogated. As experimental objectives have become more complex, investigators and product developers have demanded higher fidelity models, robust characterization, and integrated service offerings that reduce time to actionable data and enhance reproducibility.

Consequently, suppliers, contract research providers, and academic consortia have expanded their portfolios to include advanced humanized rat variants, a broader range of immunodeficient strains, patient-derived xenograft collections, and precise transgenic constructs. At the same time, improvements in genome editing, breeding, and husbandry, together with enhanced phenotyping and bioassay capabilities, have reshaped how sponsors design preclinical programs. This introduction sets the stage for a deeper analysis of the structural shifts influencing model selection, sourcing strategies, regulatory touchpoints, and end-user preferences, while emphasizing the operational complexities and scientific opportunities that characterize the current landscape.

How advancements in genome engineering, PDX capabilities, and integrated service delivery are redefining translational value and experimental reproducibility

The landscape for humanized rodent models is undergoing transformative shifts driven by converging technological, operational, and scientific forces. First, precision genome engineering and refined immunoengraftment methods have increased the fidelity of humanized immune systems and organ-specific phenotypes, enabling more predictive assessments of immunotherapies and biologics. At the same time, the proliferation of patient-derived xenograft collections and improved cryopreservation practices have accelerated translational oncology programs by preserving tumor heterogeneity and clinical relevance.

Meanwhile, the industry is experiencing a move toward modular service delivery where model provision, efficacy testing, and screening services are bundled to streamline sponsor workflows and reduce administrative friction. Regulatory scrutiny and heightened reproducibility expectations have spurred more rigorous documentation, standardized endpoints, and third-party quality audits. In parallel, computational integration-combining in vivo data with multi-omic readouts and advanced analytics-has emerged as a core capability for unlocking mechanistic insight and optimizing study design. Collectively, these shifts are fostering a more collaborative ecosystem in which cross-disciplinary partnerships, vertical integration, and platform-based approaches define competitive advantage and scientific value.

Assessing how 2025 tariff adjustments shaped supply resilience, procurement strategies, and vendor diversification in preclinical research ecosystems

The cumulative policy adjustments and tariff measures enacted in and around 2025 have exerted a multifaceted impact on supply chains and operational planning for organizations that rely on specialized animal models and contiguous laboratory inputs. For many end users, the immediate effect has been an increase in landed costs for imported breeding stock, specialized consumables, and certain reagents, which has prompted procurement teams to renegotiate supplier agreements, consolidate orders, and prioritize vendors with geographically diversified manufacturing footprints. In response, several providers have adapted by relocating critical production steps, increasing domestic breeding capacity where feasible, and expanding local inventories to buffer against longer lead times.

Beyond direct cost effects, tariffs have influenced decisions about sourcing strategy and vendor selection, reinforcing the importance of contractual flexibility and transparent lead-time commitments. In cases where cross-border logistics became less predictable, sponsors accelerated validation programs for alternative models and suppliers to preserve experimental timelines. Moreover, adjustments in trade policy have elevated compliance requirements and documentation burdens, obliging laboratory and procurement teams to strengthen customs expertise and risk management practices. Taken together, these dynamics have encouraged a shift toward more resilient supply networks, greater emphasis on supplier qualification, and strategic investments in redundancy to protect critical preclinical workflows.

Deep segmentation intelligence revealing how model type, application focus, end-user priorities, and product-service configurations drive procurement and R&D choices

Disaggregating the humanized rodent landscape by model type, application, end user, and product typology reveals targeted strategic implications for R&D planners and procurement leaders. When examined by model type, the market encompasses humanized rat models, immunodeficient models, PDX models, and transgenic models. The humanized rat models category includes hACE2 rat models and hCD4 rat models, which are particularly relevant for viral tropism studies and immuno-oncology investigations respectively. Immunodeficient models further comprise NOG models, NSG models, and SCID models, with variation in engraftment efficiency, immunophenotype, and suitability for diverse xenograft and human immune system reconstitution workflows. Patient-derived xenograft models span breast cancer PDX, colorectal cancer PDX, and lung cancer PDX, offering disease-specific fidelity that supports therapeutic hypothesis testing and biomarker discovery. Transgenic models that are leveraged for mechanistic interrogation and target validation include both knock-in models and knock-out models, each providing distinct advantages for studying gene function and pathway modulation.

Viewed by application, the portfolio aligns with cardiovascular, immunology, infectious disease, neurology, and oncology research needs. Cardiovascular applications include atherosclerosis models and hypertension models that support drug safety and mechanism studies, while immunology applications cover autoimmune disorder models and inflammatory disease models that are critical to biologics development. Infectious disease applications are differentiated into bacterial infection models and viral infection models, a distinction that guides choices around host susceptibility and biosafety. Neurology applications include neurodegenerative disease models and pain models that help translate CNS-targeted therapies, and oncology applications divide into hematological models and solid tumor models depending on tumor microenvironment considerations. End users are typified by academic research institutes, contract research organizations, and pharmaceutical and biotech companies, each adopting different procurement timelines, validation thresholds, and service preferences. Finally, product type distinctions comprise model products and services. Model products are subdivided into commercial models and custom models that address off-the-shelf versus bespoke needs, while services include efficacy testing services, model development services, and screening services that support study execution and translational validation.

Taken together, these segment dimensions indicate that decisions around model selection are increasingly driven by a combination of biological fidelity, service integration, and operational certainty. Sponsors focused on immunotherapies often favor highly characterized immunodeficient strains and tailored humanized constructs, while oncology teams frequently prioritize PDX collections that preserve tumor heterogeneity. Academic institutes are more likely to adopt open-source or academic-sourced models for exploratory work, whereas pharmaceutical and biotech companies emphasize GLP-compliant vendors, reproducible supply chains, and turnkey service packages. Service differentiation-particularly in model development and efficacy testing-has become a principal competitive lever, enabling suppliers to capture longer-term partnerships and reduce transactional friction for complex programs.

Comparative regional analysis detailing how Americas, Europe, Middle East & Africa, and Asia-Pacific differential strengths influence model sourcing, compliance, and service adoption

Regional dynamics shape supply-side capabilities, regulatory interactions, and adoption trajectories for humanized rodent models in distinct ways. In the Americas, a concentration of biotech hubs, strong translational pipelines, and a mature contract research sector support high adoption of advanced humanized constructs and PDX platforms. This region benefits from considerable laboratory infrastructure and a robust service-provider network, which collectively lower barriers to entry for complex in vivo programs, but also face cost pressures related to labor and regulatory compliance. In contrast, Europe, Middle East & Africa displays a heterogeneous landscape where pockets of excellence in academic centers and specialized providers coexist with varied regulatory frameworks and reimbursement environments. This diversity yields opportunities for cross-border collaborations and specialized niche services, yet it also requires careful navigation of differing animal welfare standards and import/export regulations.

The Asia-Pacific region has seen rapid capacity expansion in breeding facilities, CRO services, and translational research hubs, coupled with an increasing number of domestically developed model lines and a growing emphasis on local manufacturing of reagents. As a result, this region offers competitive pricing and scale advantages for sponsors pursuing large preclinical programs, though stakeholders should assess supplier quality systems and documentation to ensure alignment with global regulatory expectations. Across all regions, logistical factors, customs processes, and regional policy shifts influence lead times and supplier selection. Consequently, multinational programs often adopt hybrid sourcing strategies that combine local capacity for routine studies with international partners for highly specialized or validated model systems.

Insights into supplier strategies, service integration, proprietary model development, and partnerships that define competitive advantage in preclinical services

Competitive dynamics among suppliers and service providers are characterized by a mix of specialization and consolidation, as firms pursue vertical integration, proprietary model libraries, and value-added service bundles. Leading providers increasingly invest in cryopreserved PDX banks, advanced phenotyping platforms, and proprietary humanization protocols to secure durable client relationships and create technical differentiation. Parallel to this, contract research organizations are expanding their in vivo capabilities through strategic alliances, capacity investments, and the addition of GLP-compliant facilities to support late-stage therapeutic programs.

Innovation is concentrated around improving engraftment efficiency, reducing xenograft variability, and expanding the repertoire of transgenic constructs tailored to specific mechanistic questions. Providers that excel in quality systems, traceability, and regulatory documentation have a competitive advantage when engaging with large pharmaceutical sponsors who require stringent supplier qualification. In addition, service models that integrate model development, efficacy testing, and biomarker readouts enable suppliers to move up the value chain and capture a greater share of sponsor spend. Finally, partnerships with academic centers and hospital networks are becoming more common, facilitating access to fresh tumor specimens for PDX generation and enabling translational collaborations that accelerate target validation and clinical translation.

Actionable strategic steps leaders should implement to enhance supplier resilience, translational validity, regulatory readiness, and service integration

Industry leaders can adopt a set of pragmatic actions to strengthen operational resilience, scientific rigor, and commercial positioning in the evolving humanized rodent ecosystem. First, prioritize supplier qualification processes that include documentation of breeding records, genetic validation, and engraftment performance, and integrate those criteria into long-term procurement agreements to reduce variability. Second, invest in dual-sourcing strategies and regional redundancy for critical models and reagents in order to mitigate disruptions from policy shifts or logistics constraints, thereby preserving study timelines.

Third, foster internal capabilities for translational assay development and data harmonization so that in vivo findings can be more readily integrated with multi-omic and imaging readouts, increasing the predictive value of preclinical programs. Fourth, negotiate service-level commitments with CRO partners that include clearly defined timelines, contingency plans, and mutual performance metrics to align incentives and reduce downstream delays. Fifth, accelerate the adoption of standardized reporting formats and metadata frameworks across studies to enhance reproducibility and facilitate regulatory engagement. Sixth, pursue strategic collaborations with clinical centers and biobanks to expand access to diverse PDX sources and to enrich translational relevance. Seventh, allocate resources to continuous staff training on animal welfare, biosafety, and regulatory compliance to ensure ethical and high-quality study conduct. Finally, evaluate commercialization opportunities for proprietary models and platform services, balancing licensing potential with the operational demands of scale and quality assurance.

A transparent, triangulated research approach combining expert interviews, documentary analysis, and validation checks to produce reliable strategic insights for stakeholders

The research methodology underpinning this analysis combined structured primary inquiry, rigorous secondary review, and iterative validation to ensure the findings are robust and actionable. Primary inputs included interviews with scientific leaders, procurement managers, and CRO executives to capture real-world decision criteria, lead-time sensitivities, and evolving service expectations. Secondary review encompassed peer-reviewed literature, regulatory guidance documents, technical product literature, and operational reports to map technological trajectories and quality standards. These qualitative and documentary inputs were synthesized to develop a segmentation framework, scenario analyses for supply-chain impacts, and comparative regional assessments.

To validate conclusions, triangulation was employed through cross-referencing interview insights with supplier literature and operational performance indicators, and follow-up consultations were conducted to reconcile divergent perspectives. Quality control procedures included standardized interview guides, source attribution logs, and a reproducibility checklist that documented key assumptions. The methodology acknowledges limitations tied to proprietary supplier data and the rapidly changing policy environment; as such, readers are encouraged to treat the insights as strategic guidance that should be augmented with firm-specific due diligence when making procurement or R&D decisions.

Final synthesis emphasizing why integration of scientific fidelity, supplier qualification, and operational resilience is essential for translational success

In conclusion, humanized mouse and rat models represent a vital nexus between experimental biology and clinical translation, with ongoing innovations in genetic engineering, PDX preservation, and integrated service delivery redefining preclinical strategy. The interplay of technological progress, regulatory expectations, and supply-chain dynamics requires sponsors to adopt more sophisticated procurement, qualification, and collaboration practices. As tariff and policy environments evolve, organizations that invest in supplier diversification, rigorous documentation, and translational assay integration will be better positioned to sustain program momentum and extract higher predictive value from in vivo studies.

Ultimately, the competitive landscape rewards those who combine scientific excellence with operational discipline: firms that can deliver reproducible, well-characterized models alongside turnkey services will capture deeper sponsor engagement and support faster decision making. By applying the segmentation insights, regional considerations, and actionable recommendations provided herein, stakeholders can align their preclinical strategies with scientific priorities and operational realities to accelerate therapeutic development and mitigate risk.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Surge in CRISPR/Cas9 engineered humanized mouse models enhancing immuno-oncology research reproducibility
  • 5.2. Rising demand for humanized rat models to improve pharmacokinetic and toxicity profiling in preclinical studies
  • 5.3. Integration of multi-omics and humanized rodent models to accelerate personalized medicine and biomarker discovery
  • 5.4. Collaboration between biotech firms and academic institutions to develop next generation humanized rodent platforms
  • 5.5. Expansion of humanized animal model services in emerging markets driven by growing biologics pipeline investments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Humanized Mouse & Rat Model Market, by Model Type

  • 8.1. Humanized Rat Models
    • 8.1.1. hACE2 Rat Models
    • 8.1.2. hCD4 Rat Models
  • 8.2. Immunodeficient Models
    • 8.2.1. NOG Models
    • 8.2.2. NSG Models
    • 8.2.3. SCID Models
  • 8.3. PDX Models
    • 8.3.1. Breast Cancer PDX
    • 8.3.2. Colorectal Cancer PDX
    • 8.3.3. Lung Cancer PDX
  • 8.4. Transgenic Models
    • 8.4.1. Knock-In Models
    • 8.4.2. Knock-Out Models

9. Humanized Mouse & Rat Model Market, by Application

  • 9.1. Cardiovascular
    • 9.1.1. Atherosclerosis Models
    • 9.1.2. Hypertension Models
  • 9.2. Immunology
    • 9.2.1. Autoimmune Disorder Models
    • 9.2.2. Inflammatory Disease Models
  • 9.3. Infectious Disease
    • 9.3.1. Bacterial Infection Models
    • 9.3.2. Viral Infection Models
  • 9.4. Neurology
    • 9.4.1. Neurodegenerative Disease Models
    • 9.4.2. Pain Models
  • 9.5. Oncology
    • 9.5.1. Hematological Models
    • 9.5.2. Solid Tumor Models

10. Humanized Mouse & Rat Model Market, by End User

  • 10.1. Academic Research Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Pharmaceutical Biotech Companies

11. Humanized Mouse & Rat Model Market, by Product Type

  • 11.1. Model Products
    • 11.1.1. Commercial Models
    • 11.1.2. Custom Models
  • 11.2. Services
    • 11.2.1. Efficacy Testing Services
    • 11.2.2. Model Development Services
    • 11.2.3. Screening Services

12. Humanized Mouse & Rat Model Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Humanized Mouse & Rat Model Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Humanized Mouse & Rat Model Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Charles River Laboratories International, Inc.
    • 15.3.2. The Jackson Laboratory, Inc.
    • 15.3.3. Taconic Biosciences, Inc.
    • 15.3.4. Inotiv, Inc.
    • 15.3.5. PerkinElmer, Inc.
    • 15.3.6. Crown Bioscience International, Inc.
    • 15.3.7. Biocytogen Pharmaceuticals Ltd.
    • 15.3.8. BioIVT, Inc.
    • 15.3.9. Cyagen Biosciences Inc.
    • 15.3.10. GemPharmatech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HUMANIZED MOUSE & RAT MODEL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HUMANIZED MOUSE & RAT MODEL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HUMANIZED MOUSE & RAT MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HACE2 RAT MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HCD4 RAT MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NOG MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NSG MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCID MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BREAST CANCER PDX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COLORECTAL CANCER PDX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY LUNG CANCER PDX, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY KNOCK-OUT MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ATHEROSCLEROSIS MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HYPERTENSION MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY AUTOIMMUNE DISORDER MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFLAMMATORY DISEASE MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY BACTERIAL INFECTION MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY VIRAL INFECTION MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEURODEGENERATIVE DISEASE MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEURODEGENERATIVE DISEASE MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEURODEGENERATIVE DISEASE MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEURODEGENERATIVE DISEASE MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEURODEGENERATIVE DISEASE MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY NEURODEGENERATIVE DISEASE MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PAIN MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PAIN MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PAIN MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PAIN MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PAIN MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PAIN MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HEMATOLOGICAL MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HEMATOLOGICAL MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HEMATOLOGICAL MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HEMATOLOGICAL MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HEMATOLOGICAL MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HEMATOLOGICAL MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SOLID TUMOR MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SOLID TUMOR MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SOLID TUMOR MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SOLID TUMOR MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SOLID TUMOR MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SOLID TUMOR MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PHARMACEUTICAL BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COMMERCIAL MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COMMERCIAL MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COMMERCIAL MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COMMERCIAL MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COMMERCIAL MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY COMMERCIAL MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CUSTOM MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CUSTOM MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CUSTOM MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CUSTOM MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CUSTOM MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CUSTOM MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY EFFICACY TESTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY EFFICACY TESTING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY EFFICACY TESTING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY EFFICACY TESTING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY EFFICACY TESTING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY EFFICACY TESTING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL DEVELOPMENT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL DEVELOPMENT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL DEVELOPMENT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL DEVELOPMENT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL DEVELOPMENT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCREENING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCREENING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCREENING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCREENING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCREENING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SCREENING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY HUMANIZED RAT MODELS, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNODEFICIENT MODELS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY PDX MODELS, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY TRANSGENIC MODELS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY IMMUNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS HUMANIZED MOUSE & RAT MODEL MARKET SIZE, BY INFECTIOUS DISEASE,